The estimated Net Worth of Steven Pieper is at least $3.37 Milione dollars as of 20 November 2023. Mr Pieper owns over 28,000 units of Xeris Biopharma Inc stock worth over $3,365,968 and over the last 3 years he sold XERS stock worth over $0.
Mr has made over 2 trades of the Xeris Biopharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of XERS stock worth $54,600 on 20 November 2023.
The largest trade he's ever made was buying 28,000 units of Xeris Biopharma Inc stock on 20 November 2023 worth over $54,600. On average, Mr trades about 6,625 units every 93 days since 2021. As of 20 November 2023 he still owns at least 1,176,912 units of Xeris Biopharma Inc stock.
You can see the complete history of Mr Pieper stock trades at the bottom of the page.
Steven M. Pieper is the Chief Financial Officer at Xeris Biopharma Inc.
Mr Pieper is 44, he's been the Chief Financial Officer of Xeris Biopharma Inc since . There are 19 older and no younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... e Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Xeris Biopharma Inc executives and other stock owners filed with the SEC include: